Year-end Sale % OFF 
Abstract
Despite the availability of the drug treatment for tuberculosis (TB) more than 75 years, mortality and drug resistance are increasing. Therefore, little data is available in Guinea. We aimed to develop and validate a prognosis nomogram of MDR-TB treatment outcomes. A retrospective cohort study was conducted among men and women, aged 18 years or older, with MDR-TB, from three major drug-resistance TB centres in Guinea. We used the logistic regression to analyse treatment outcomes. Prognostic factors with a p value less than 0.05 from a multivariate model were used to build nomogram and assessed their performance based on discriminative <i>c-index</i>, and calibration using the Hosmer-Lemeshow (H-L) test. To derive the optimal cut-off point score, the Youden’s index method was used. Among 232 patients with MDR-TB enrolled and followed between June 07, 2016 and June 22, 2018, 218 were analyzed. All patients were resistant to rifampicin, which diagnosed by the Xpert MTB/RIF. The overall rate of success was 73%. Factors associated with successful treatment in drug-resistant TB patients were higher BMI more than 18.5 kg/m<sup>2</sup> (p = 0.0253; aOR = 2.94), good adherence to treatment (p = < 0.0001; aOR = 33.92), normal platelets count (p = 0.0053; OR = 1.004), and the absence of clinical symptoms such as chest pain (p = 0.0083; aOR = 3.19) and depression (p = 0.0308; aOR = 8.62). The discrimination (<i>c-index</i> = 0.848 [95% bootstrap CI, 0.780 – 0.916] in the derivation sample and 0.803 after correction for optimism) and calibration (H-L<sub>X</sub><sup>2</sup> = 2.91 [p = 0.94]) were good. The optimal absolute risk threshold was 20%, corresponding to a sensibility of 95% and specificity of 58%. Treatment success outcomes was lower than those recommended by the World Health Organization (75%). We recommend to improve the MDR-TB patient monitoring during treatment, nutritional status, and considering the psychological state. Our prognosis nomogram needs to be validated in an external population before it can be used in clinical practice.
Highlights
Despite the availability of the drug treatment for tuberculosis (TB) since 1943, mortality and drug resistance are increasing, mainly because the emergence of the human immunodeficiency virus (HIV) infection, the poor prevention programs, and the persisting global poverty [1].Multidrug-resistant (MDR)-TB is defined as resistance at least to isoniazid (INH) and rifampicin (R) with an estimatedBoubacar Djelo Diallo et al.: Development of a Prognosis Nomogram of Treatment Outcomes for MDR-tuberculosis in Guinea (Conakry): A Retrospective Cohort Analysis600 000 new cases reported by the World Health Organization (WHO) in 2016 [2]
Compared to the recently published studies [4,5,6,7,8,9,10], our success rate was higher than those reported in Morocco (53.5%) [5], Brazil (60%) [4], and in Bashkortostan region of Russia (67%) [11], comparable to those reported in Baluchistan province of Pakistan (71.6%) [8] and Tanzania (75.7%) [6], and lower than those reported, in Yemen (77.4%) [7], Eastern Taiwan (78.4%) [9], and Rwanda (87.3%) [10]
After 9-months Multidrug-resistant tuberculosis (MDR-TB) treatment, 7% of our patients were lost to follow-up, which was higher to those reported in Rwanda (0.6%) [10], comparable to those reported in Baluchistan province of Pakistan (7.5%) [8], and lower than those reported recently in several studies [4, 6, 9] as in Morocco where 34.6% of patients lost to follow-up [5]
Summary
Despite the availability of the drug treatment for tuberculosis (TB) since 1943, mortality and drug resistance are increasing, mainly because the emergence of the HIV infection, the poor prevention programs, and the persisting global poverty [1].Multidrug-resistant (MDR)-TB is defined as resistance at least to isoniazid (INH) and rifampicin (R) with an estimatedBoubacar Djelo Diallo et al.: Development of a Prognosis Nomogram of Treatment Outcomes for MDR-tuberculosis in Guinea (Conakry): A Retrospective Cohort Analysis600 000 new cases reported by the World Health Organization (WHO) in 2016 [2]. Despite the availability of the drug treatment for tuberculosis (TB) since 1943, mortality and drug resistance are increasing, mainly because the emergence of the HIV infection, the poor prevention programs, and the persisting global poverty [1]. Boubacar Djelo Diallo et al.: Development of a Prognosis Nomogram of Treatment Outcomes for MDR-tuberculosis in Guinea (Conakry): A Retrospective Cohort Analysis. While Russia, China, and India accounted 47% of the global incident cases of MDRTB [2], little data is available in Guinea. According to the national tuberculosis program reports, the number of new incident cases of MDR-TB has increased from 53 in 2008 to 265 cases in 2018 [3]. A recent meta-analysis identified negative HIV infection and non-use alcohol misuse as predictors associated with successful treatment [12]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
